| Type 2 Diabetes Mellitus |
1 |
1 |
| SGLT2 Inhibitor |
0 |
0.99 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.7 |
| GLP-1 Receptor Agonist |
0 |
0.88 |
| Receptors |
0 |
0.41 |
| Chronic Kidney Disease |
0 |
0.9 |
| Renal Failure |
0 |
0.37 |
| Renal Disease |
0 |
0.33 |
| Revenue and Practice Management |
0 |
0.2 |
| Hospital |
0 |
0.17 |
| Washington |
0 |
0.17 |
| Cardiovascular Risk Management |
0 |
0.14 |
| Patient Safety |
0 |
0.14 |
| Heart Failure (HF) |
0 |
0.13 |
| Coronary Artery Disease (CAD) |
0 |
0.12 |
| Heart |
0 |
0.08 |
| Medicare |
0 |
0.08 |
| Health Insurance |
0 |
0.06 |
| Social Determinants of Health |
0 |
0.05 |
| Weight Management |
0 |
0.05 |
| Adverse Effects |
0 |
0.04 |
| Biomarker |
0 |
0.04 |
| Biopsy |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Clinical Guidelines |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Emesis |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Health Care Quality, Access, and Evaluation |
0 |
0.04 |
| Insurance |
0 |
0.04 |
| Sulfonylureas |
0 |
0.04 |
| Weight Loss |
0 |
0.04 |